Wojciech Jurczak
Professor, Head of Clinical Oncology Department
Maria Sklodowska-Curie National Research Institute of Oncology · Krakow, Poland
Key investigator in the SYMPATICO trial (ibrutinib + venetoclax in MCL). Active in European MCL Network clinical trials.
Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial).
Annals of hematology · Jul 17, 2026
Erratum: Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 14, 2026
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.
British journal of haematology · Jul 12, 2026
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations.
Blood · Jul 1, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 1, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
The Lancet. Haematology · May 1, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Current medical research and opinion · Dec 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.
Haematologica · Mar 1, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
The Lancet. Oncology · Feb 1, 2025
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Haematologica · Jan 1, 2025
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.
Blood advances · Sep 10, 2024